Edition:
India

Horizon Pharma Announces FDA Approval to Expand the Indication for Procysbi


Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Horizon Pharma Plc ::HORIZON PHARMA PLC ANNOUNCES FDA APPROVAL TO EXPAND THE INDICATION FOR PROCYSBI® (CYSTEAMINE BITARTRATE) DELAYED-RELEASE CAPSULES TO INCLUDE CHILDREN ONE YEAR OF AGE AND OLDER LIVING WITH NEPHROPATHIC CYSTINOSIS. 

Company Quote

24.52
-0.08 -0.33%
9:13pm IST